R&G PharmaStudies Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 23.94%

R&G PharmaStudies Co. Ltd. A (301333) has an Asset Resilience Ratio of 23.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥574.90 Million

≈ $84.13 Million USD Cash + Short-term Investments

Total Assets

CN¥2.40 Billion

≈ $351.41 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how R&G PharmaStudies Co. Ltd. A's Asset Resilience Ratio has changed over time. See R&G PharmaStudies Co. Ltd. A (301333) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down R&G PharmaStudies Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see R&G PharmaStudies Co. Ltd. A (301333) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥574.90 Million	23.94%
Total Liquid Assets	CN¥574.90 Million	23.94%

Asset Resilience Insights

Good Liquidity Position: R&G PharmaStudies Co. Ltd. A maintains a healthy 23.94% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

R&G PharmaStudies Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare R&G PharmaStudies Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for R&G PharmaStudies Co. Ltd. A (2023–2025)

The table below shows the annual Asset Resilience Ratio data for R&G PharmaStudies Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	25.84%	CN¥620.12 Million ≈ $90.74 Million	CN¥2.40 Billion ≈ $351.14 Million	-4.45pp
2024-12-31	30.29%	CN¥707.61 Million ≈ $103.55 Million	CN¥2.34 Billion ≈ $341.86 Million	-4.06pp
2023-12-31	34.35%	CN¥712.39 Million ≈ $104.24 Million	CN¥2.07 Billion ≈ $303.46 Million	--

pp = percentage points

About R&G PharmaStudies Co. Ltd. A

SHE:301333 China Biotechnology

Market Cap

$716.54 Million

CN¥4.90 Billion CNY

Market Cap Rank

#10343 Global

#2731 in China

Share Price

CN¥50.70

Change (1 day)

+7.14%

52-Week Range

CN¥44.50 - CN¥91.20

All Time High

CN¥91.20